This Article Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (53) Citing Articles via Google Scholar Google Scholar Articles by Dubois, R. W. Articles by Wade, S. Search for Related Content PubMed PubMed Citation Articles by Dubois, R. W. Articles by Wade, S. Related Collections Pharmaceuticals Health Spending

Health Affairs, Vol 19, Issue 2, 231-239
Copyright © 2000 by Project HOPE

DataWatch

Explaining drug spending trends: does perception match reality?

Several recent studies have made clear that drug expenditures are rising more rapidly than other health care spending. What has not been clear, however, is how much drug spending is driven by price rather than volume and whether volume increases are appropriate. This DataWatch takes a closer look at the components and drivers of drug spending using large claims databases from managed care and employer-sponsored health benefit plans. In both environments this study found volume, not price, to be the largest driver of drug spending for seven diseases studied. For four of the diseases, we review the clinical issues that may have influenced volume growth.

                      What's this?

This article has been cited by other articles:

				L. Liu, R. R Cline, S. W Schondelmeyer, and J. C Schommer Pharmaceutical Expenditures as a Correlate of Population Health in Industrialized Nations Ann. Pharmacother., March 1, 2008; 42(3): 368 - 374. [Abstract] [Full Text] [PDF]

				J. D. Piette and E. A. Kerr The impact of comorbid chronic conditions on diabetes care. Diabetes Care, March 1, 2006; 29(3): 725 - 731. [Full Text] [PDF]

				J. F. Moeller, G. E. Miller, and J. S. Banthin Looking Inside The Nation's Medicine Cabinet: Trends In Outpatient Drug Spending By Medicare Beneficiaries, 1997 And 2001 Health Aff., September 1, 2004; 23(5): 217 - 225. [Abstract] [Full Text] [PDF]

				J. D. Piette, M. Heisler, and T. H. Wagner Problems Paying Out-of-Pocket Medication Costs Among Older Adults With Diabetes Diabetes Care, February 1, 2004; 27(2): 384 - 391. [Abstract] [Full Text] [PDF]

				U. Sambamoorthi, D. Shea, and S. Crystal Total and Out-of-Pocket Expenditures for Prescription Drugs Among Older Persons Gerontologist, June 1, 2003; 43(3): 345 - 359. [Abstract] [Full Text] [PDF]

				M. E. Hemels, H. A Bennett, L. Bonari, D. Han, M. L Traverso, and T. R Einarson HOPE Study Impact on ACE Inhibitors Use Ann. Pharmacother., May 1, 2003; 37(5): 640 - 645. [Abstract] [Full Text] [PDF]

				G. F. Joyce, J. J. Escarce, M. D. Solomon, and D. P. Goldman Employer Drug Benefit Plans and Spending on Prescription Drugs JAMA, October 9, 2002; 288(14): 1733 - 1739. [Abstract] [Full Text] [PDF]

				J. E. Calfee Pharmaceutical Price Controls and Patient Welfare Ann Intern Med, June 5, 2001; 134(11): 1060 - 1064. [Abstract] [Full Text] [PDF]

				J. K. Iglehart Medicare and Prescription Drugs N. Engl. J. Med., March 29, 2001; 344(13): 1010 - 1015. [Full Text] [PDF]

				V. A. Freedman, H. Aykan, and L. G. Martin Aggregate Changes in Severe Cognitive Impairment Among Older Americans: 1993 and 1998 J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2001; 56(2): 100S - 111. [Abstract] [Full Text]